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Abstract
Background: The World Health Organisation recommends the use of catch-up campaigns as part of the
introduction of pneumococcal conjugate vaccines (PCVs) to accelerate herd protection and hence PCV impact. The
value of a catch-up campaign is a trade-off between the costs of vaccinating additional age groups and the benefit
of additional direct and indirect protection. There is a paucity of observational data, particularly from low- and
middle-income countries, to quantify the optimal breadth of such catch-up campaigns.
Methods: In Kilifi, Kenya, PCV10 was introduced in 2011 using the three-dose Expanded Programme on
Immunisation infant schedule and a catch-up campaign in children <5 years old. We fitted a transmission dynamic
model to detailed local data, including nasopharyngeal carriage and invasive pneumococcal disease (IPD), to infer
the marginal impact of the PCV catch-up campaign over hypothetical routine cohort vaccination in that setting and
to estimate the likely impact of alternative campaigns and their dose efficiency.
Results: We estimated that, within 10 years of introduction, the catch-up campaign among children <5 years old
prevents an additional 65 (48–84) IPD cases across age groups, compared to PCV cohort introduction alone.
Vaccination without any catch-up campaign prevented 155 (121–193) IPD cases and used 1321 (1058–1698) PCV
doses per IPD case prevented. In the years after implementation, the PCV programme gradually accrues herd
protection, and hence its dose efficiency increases: 10 years after the start of cohort vaccination alone the
programme used 910 (732–1184) doses per IPD case averted. We estimated that a two-dose catch-up among
children <1 year old uses an additional 910 (732–1184) doses per additional IPD case averted. Furthermore, by
extending a single-dose catch-up campaign to children aged 1 to <2 years and subsequently to those aged 2
to <5 years, the campaign uses an additional 412 (296–606) and 543 (403–763) doses per additional IPD case
averted. These results were not sensitive to vaccine coverage, serotype competition, the duration of vaccine
protection or the relative protection of infants.
Conclusions: We find that catch-up campaigns are a highly dose-efficient way to accelerate population protection
against pneumococcal disease.
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Background
With the aid of Gavi, the Vaccine Alliance (Gavi for short),
many low-income countries, in particular across Africa,
have introduced pneumococcal conjugate vaccines (PCVs)
into their infant immunisation programmes. However,
there remain Gavi countries, particularly in south Asia
and northern Africa and some with large infant popula-
tions, who are yet to follow [1]. Country policy makers,
along with global stakeholders, have a high interest in
achieving optimal health impact from PCVs as quickly as
possible; however, approaches for achieving maximum
and rapid impact have to be weighed against relative cost.
In situations where vaccine supply is constrained, as was
the case several years ago for PCVs, issues of efficiency
and equity in vaccine use are also a consideration [2]. The
World Health Organisation (WHO) recommends that
catch-up campaigns can be used as part of the introduc-
tion of PCVs to accelerate the build-up of herd protection
and hence PCV impact [3]. However, it is unclear if such
catch-up campaigns are an efficient way to use PCVs or if
the gains from this approach are less than the relative in-
crease in the number of doses required.
The value of a catch-up campaign is assessed by quan-
tifying the trade-off between the costs of vaccinating
additional age groups and the benefit of additional direct
and indirect protection. However, there are few observa-
tional data on the impact of PCV campaigns, particularly
from low- and middle-income countries (LMICs), to
quantify the optimal approach of catch-up campaigns.
One of the few well-studied examples of a PCV intro-
duction catch-up campaign in an LMIC occurred in
Kilifi, Kenya. The 10-valent pneumococcal non-typeable
Haemophilus influenzae protein D-conjugate vaccine
(PCV10) was introduced into the Kenyan routine
childhood vaccination programme in early January 2011
using the WHO Expanded Programme on Immunisation
(EPI) schedule of three infant doses at 6, 10 and 14 weeks.
Additionally, in Kilifi County, at the introduction of the
cohort programme, a three-dose catch-up campaign was
offered to all infants younger than 12 months of age and a
two-dose catch-up to children 12–59 months of age.
We fitted a transmission dynamic model of pneumococ-
cal carriage (a precondition for disease and the source of
person-to-person community transmission) and disease to
detailed pre- and post-PCV introduction data from Kilifi.
This allowed us to quantify the marginal impact of the
PCV catch-up campaign on carriage and disease in Kilifi
over the hypothetical impact of a routine cohort vac-
cination programme alone in that setting. Using this
framework, we aimed to estimate the dose efficiency of
alternative catch-up campaigns in relation to PCV cohort
introduction alone.
Methods
Data
Study population and mixing patterns
Kilifi County is a mainly rural area on the Indian Ocean
coast of Kenya. The Kilifi Health and Demographic
Surveillance System (KHDSS) was established in 2000.
Approximately 260,000 people reside in the KHDSS
area, and 60% are younger than 20 years of age [4]. Within
the KHDSS numerous studies regarding pneumococcus
and its health effects have been conducted that informed
this work (Table 1). The demographic structure of the
model is based on 2009 mid-year population census esti-
mates and assumes no demographic changes with time.
To adjust for changes in the population age distribution,
we used respective annual mid-year population estimates
Table 1 Overview of model parameters
Model parameters Contribution No. of parameters Prior Posterior
Distribution Mean SD Source Median CR
Study population Age group size Fixed 6 age groups – – – KHDSS [4] – –
Contact patterns Fixed 6 × 6 age groups – – – KHDSS [5] – –
Carriage prevalence Outcome 2 types × 6 age groups – – – KHDSS [11] – –
IPD Outcome 2 types × 6 age groups – – – KHDSS [12] – –
Observed vaccine coverage Fixed 27,040 (weekly age
and time)
– – – KHDSS [4] – –
Transmission dynamics Clearance rates Fixed 2 types × 4 age groups KHDSS [15]
VE carriage (toddlers) Fitted - prior 1 Normal 0.36 0.15 KHDSS [11] 0.56 0.41–0.72
VE IPD (infants) Fitted - prior 1 Normal 0.80 0.1 [22] 0.86 0.67–0.99
Duration of protection (toddlers) Fitted - prior 1 Normal 6 years 3 [23, 24] 5.50 2.05–11.01
Relative level of infant protection Fitted - prior 1 Normal 1 0.1 Assumption 0.97 0.78–1.17
Competition parameter Fitted - prior 1 Log-normal 0.15 0.15 [17, 18] 0.19 0.07–0.44
Susceptibility to infection Fitted - no prior 2 types × 4 age groups
Invasiveness Fitted - no prior 2 types × 4 age groups
CR Credible range, VE Vaccine efficacy
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to calculate the invasive pneumococcal disease (IPD) inci-
dence rates. A cross-sectional prospective diary-based
contact survey was conducted in the northern part of
the KHDSS area in 2009 [5, 6]. In total, 623 randomly
selected participants of all ages produced 568 com-
pleted diaries in which they reported their contacts
during 24 hours and reported 27,395 physical (i.e. skin-
to-skin) contacts with 10,042 unique individuals. This
information was used as a proxy for transmission of
pneumococcal carriage [7, 8]. Standard methods were
used to calculate the WAIFW (Who Acquires Infection
From Whom) mixing matrix for age groups <1 year, 1–
5 years, 6–15 years, 16–19 years, 20–49 years and older
than 50 years for the KHDSS [5, 8–10].
Pneumococcal carriage and IPD
The model was fitted to vaccine type (VT) and non-
vaccine type (NVT) carriage prevalence and IPD inci-
dence between 2009 and 2015 and between 2008 and
2015, respectively. During that period annual cross-
sectional carriage surveys were conducted in the KHDSS
area [11]. In each study a nasopharyngeal swab was
collected from more than 500 randomly selected individ-
uals of all ages. Surveillance with passive case finding for
IPD was introduced at Kilifi County Hospital in 1998 for
children and in 2007 for adults. Among the residents of
the KHDSS area, 30–70 cases of IPD have been reported
annually [12]. Much of that variation is due to changes
in disease caused by serotype 1, which has been reported
previously to be unstable in various settings [13, 14]. As
the mechanisms behind serotype 1 epidemic behaviour
are poorly understood, we used multiple pre-vaccination
years to include this variance into our baseline for the
predictions.
Duration of carriage
We used average age-specific pneumococcal colonisation
clearance rates estimated from a longitudinal carriage
survey in the KHDSS area [15] and reported for the age
groups <22 months, 22–40 months and 41–59 months.
Based on other studies [16], we assumed that clearance
rates in individuals older than 5 years were 60% higher
than in children of age 2–4 years.
Serotype competition
The competition parameter, which determines the pro-
portion by which the likelihood of acquisition is reduced
by heterologous carriage, based on local data was only
estimated as serotype specific [15] rather than for pooled
VT and NVT groups. Thus, we used a log-normal prior
distribution with a median of 0.11 based on estimates
from other settings [17–19].
Vaccine coverage
As part of the KHDSS, electronic individual-based re-
cords of the delivery of vaccines are routinely collected
at vaccine clinics [20]. We calculated weekly estimates of
PCV coverage for the 2 years after PCV introduction;
each was stratified by weekly age cohorts from newborns
up to 5 years of age (Additional file 1: Figure S2). Two
such coverage estimates were calculated: vaccine cover-
age of at least two doses of PCV administered before the
age of 1 year, which was deemed ’infant protection’, and
vaccine coverage of at least one dose of PCV adminis-
tered after the age of 1 year, deemed ’toddler protection’.
The choice of at least two doses for infants and at least
one dose for toddlers was made on the basis of observed
coverage rates. For calculation of the number of doses
used, we assumed that vaccinated infants within the rou-
tine programme received three doses, infants vaccinated
as part of the catch-up received two doses and toddlers
received one dose. Data for vaccination rates were avail-
able only through late 2012; we extrapolated those rates
forward in time by assuming the coverage rates as of
later 2012 to continue for the rest of the study period.
Vaccine efficacy
The efficacy against VT nasopharyngeal carriage of a
single dose of PCV10 administered to children 12–59
months old has been estimated in a randomised con-
trolled trial in Kenya at 36% (95% confidence interval: –
1 to 60) [21]. We further assumed that vaccine efficacy
of PCV10 against VT IPD of a complete primary series
was 80% based on a meta-analysis for PCVs for infants
elsewhere [22]. These two estimates of vaccine efficacy
against VT carriage and VT IPD were used as priors in
the fitting process. Those who were vaccinated in in-
fancy, i.e. before 1 year of age, may have different vac-
cine efficacy against acquisition of colonisation, different
vaccine efficacy against progression to invasive disease
and different duration of protection than vaccinated
toddlers. We allowed for the model to estimate these
three parameters for infants as a common proportion of
respective parameters for toddlers, under the null hy-
pothesis that no difference exists.
Duration of vaccine protection
As estimates of the duration of protection from PCV
were not available from studies within the KHDSS, we
used estimates derived from external studies. Hence our
prior on the average duration of protection against car-
riage and disease is centred around 6 years [16, 23, 24].
Vaccine protection is modelled as leaky protection [25].
Model
We used a Susceptible, Infected and Infectious, Suscep-
tible type model of the transmission of grouped vaccine
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and non-vaccine pneumococcal serotypes as described
previously [16, 17]. The group of vaccine serotypes con-
sisted of all pneumococcal serotypes targeted by PCV10,
i.e. serotypes 1, 4, 5, 6B, 7 F, 9 V, 14, 18C, 19 F and 23 F.
Individuals were grouped into compartments by their
age (weekly age groups until 5 years of age and yearly
age groups thereafter), their infection status (either sus-
ceptible, infected with a vaccine serotype, a non-vaccine
serotype or both at the same time) and by their vaccin-
ation status (unprotected, infant protection, toddler pro-
tection). At acquisition of carriage an age-group- and
serotype-group-specific proportion of carriers develop
disease. These proportions were estimated from the
model alongside vaccine efficacy against carriage and
IPD, duration of protection, the relative level of infant
protection, the competition parameter and the suscepti-
bility to infection (Table 1).
Adaptive Markov chain Monte Carlo methods were
used to fit the model to the observed data (Fig. 1) [26].
A Poisson likelihood was used for IPD, and a multi-
nomial likelihood was used for carriage prevalence. We
used a Metropolis-Hastings algorithm to create samples
from the posterior parameter distributions. Prior infor-
mation was used according to their availability as de-
scribed earlier (Table 1 and Fig. 1).
Vaccination scenarios
After fitting the model parameters to match the ob-
served rates of pneumococcal carriage and disease in the
KHDSS, we created multiple hypothetical PCV introduc-
tion scenarios to determine what would have happened
if PCV10 had been introduced using different catch-up
strategies. For this we define three alternative vaccination
scenarios which assumed that administration of vaccines
followed exactly the vaccine uptake that was observed in
Kilifi for the respective age groups and assumed that no
vaccines were administered outside the age range targeted
by the scenario. These scenarios were:
1. U5 catch-up (observation and extrapolation):
Vaccination according to observed vaccine coverage
in KHDSS (i.e. all children under 5 years of age)
2. U2 catch-up (hypothetical): Vaccination according
to observed vaccine coverage in KHDSS for all
children under 2 years of age
3. U1 catch-up (hypothetical): Vaccination according
to observed vaccine coverage in KHDSS for all
children under 1 year of age
4. Cohort introduction (hypothetical): Vaccination
according to observed vaccine coverage in KHDSS
only for those children eligible for vaccination
through cohort introduction
Sensitivity analysis
We studied how competition, the duration of protection,
the relative protection of infants if compared to toddlers
and the vaccine efficacy against carriage and IPD within
the range of their posterior distribution affected our
Fig. 1 Model fit to carriage prevalence and IPD incidence (a) and prior and posterior parameter estimates (b). We assumed that serotyping
methods would only pick up the predominant serotype and that in case of co-colonisation this was always the vaccine serotype. Points with 95 `
confidence bounds represent data, and lines with ribbons represent median model estimates with 95% credible intervals. In b the grey line indicates
the prior density distribution and the bars the posterior sample
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main outcome, i.e. the number of vaccine doses needed
to prevent a case of IPD (NVN) and the ratio of NVNs
of the considered introduction strategies. We used a
multivariable linear regression model on the centred
posterior samples and reported the 95% credible interval
limits of the joint distribution of the respective param-
eter posterior and the model coefficient as a measure of
the sensitivity of the NVN ratio to the considered
parameters.
We separately assessed the sensitivity of our finding to
variable coverage levels in a univariate sensitivity ana-
lysis. Rather than using the observed coverage levels in
Kilifi, for this we assumed that protection through rou-
tine immunisation as well as the catch-up campaign
achieved either 80%, 60% or 40% coverage.
Results
Our model was able to reproduce Kilifi’s pre- and post-
vaccination epidemiology of near VT elimination across
age groups and serotype replacement with NVTs (Fig. 1).
The introduction of PCV10 together with a catch-up
campaign in children under 5 years old was predicted to
prevent 220 (172–270) cases of IPD in Kilifi within the
first 10 years after the start of the vaccination programme.
Once the full direct and indirect effects (herd protection
and serotype replacement) of the programme are estab-
lished, the vaccination programme is predicted to avert 23
(17–28) cases of IPD annually (Fig. 2a); the majority of
those among children younger than 5 years old (Fig. 1 and
Additional file 1: Figure S1).
The catch-up campaign among children up to 5 years
of age was estimated to accelerate direct and indirect
effects of PCV. By doing so the Kilifi programme was es-
timated to prevent an additional 65 (48–84) cases of IPD
(Fig. 2b) over 10 years in the overall population, if
compared to a cohort introduction without a catch-up
campaign. A catch-up programme confined to children
younger than 2 years or younger than 1 year of age was
estimated to prevent an additional 34 (26–43) or 18
(14–22) IPD cases, respectively, if compared to cohort
introduction alone. The majority of cases averted by the
catch-up campaigns would have occurred within the first
6–8 years after the start of vaccination (Fig. 2a). The age
distribution of cases averted through catch-up cam-
paigns was similar to that averted through routine im-
munisation (Additional file 1: Figure S1).
Within the first 10 years of the PCV infant programme
in Kilifi, about 205,000 doses of vaccine were predicted
to be used as part of the routine immunisation schedule.
The under 5 catch-up campaign required 17,000 add-
itional doses of vaccine (Fig. 3a). We estimated that, in
the 10 years following introduction of PCV10 in Kilifi,
routine vaccination without any catch-up campaigns
would use 1321 (1058–1698) doses of PCV for each case
of IPD averted. As herd protection gradually develops,
this programme gains efficiency in the first years after
introduction; that is, the annual number of cases pre-
vented increases while the number of vaccinated individ-
uals remains similar (Fig. 2a). By the 10th year after the
start of cohort vaccination without a catch-up campaign,
we estimated that routine vaccination uses 910 (732–
1184) doses of PCV per IPD case averted.
The number of vaccine doses needed to prevent a case
of IPD under the four scenarios is shown in Table 2.
Extending catch-up PCV immunisation to children in
the second year of life has the largest marginal efficiency,
but any catch-up campaign is more efficient than rou-
tine birth cohort immunisation. The most efficient intro-
duction strategy for PCV is introduction alongside an
under 5 year old catch-up. All differences between
schedules were found to be significant; i.e. in assessing
the relative NVN, PCV introduction including a catch-
up in children younger than 1, 2 or 5 years old was 4.6%
(3.9–5.2), 6.2% (3.7–20.0) and 8.0% (4.5–12.9) more
Fig. 2 The predicted number of cases averted by PCV10 vaccination in Kilifi if introduced with a catch-up campaign in children younger than 5, 2
or 1 year old and without catch-up campaign. Lines represent median estimates and ribbons 95% credible intervals
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efficient than introduction including no catch-up or
catch-up in children younger than 1 or 2 years old, re-
spectively. Similarly, the numbers of additional vaccine
doses needed to prevent an additional case of IPD via a
catch-up in children younger than 1, 2 or 5 years old
were 0.57 (0.54–0.61), 0.55 (0.40–0.73) and 1.32 (1.22–
1.44) of those needed to prevent an additional case via
cohort introduction alone, catch-up in children younger
than 1 or 2 years old, respectively.
Our results were not sensitive to variations in vaccine
coverage (Additional file 1: Figure S4 and Table S1) or
competition, the duration of protection, the relative pro-
tection of infants by PCV as compared to toddlers and
the vaccine efficacy against carriage and IPD (Additional
file 1: Figure S3).
Discussion
In many high-income countries PCVs have been intro-
duced with the help of catch-up campaigns to accelerate
the direct and indirect protection that is offered to the
community [27–29]. We used extensive data from the
KHDSS, a well-studied mix of rural and urban Kenyan
communities representing a typical low-income setting,
to estimate the incremental effects that different catch-
up campaigns are likely to have over routine vaccination
and, therefore, whether PCV catch-up campaigns are an
efficient use of PCV supply. We found that rapidly in-
creasing the protection in the community via catch-up
not only reduces cases of IPD by direct protection of
older children but also reduces the burden of IPD in the
whole childhood population by developing herd protec-
tion more rapidly. Any of the three catch-up programs
considered in the analysis were estimated to use fewer
vaccine doses to prevent a case of IPD than cohort
introduction during the first 10 years; the catch-up
schedules were more efficient than the routine cohort
vaccination programme alone even after full herd effects
were in place, in the 10th year of the programme. While
the additional catch-up doses given to 1 year olds were
estimated to provide the largest marginal efficiency, we
find that cohort introduction alongside a catch-up
campaign in children under 5 years old was the most
efficient introduction strategy overall.
Data on the observed impact of PCV catch-up cam-
paigns are sparse and mostly circumstantial. Catch-up
campaigns of different sizes have been used for introdu-
cing PCVs into countries including the UK [30], USA
[31], Israel [32], Brazil [33] and Kilifi, Kenya [11]. How-
ever, a head-to-head comparison with cohort introduc-
tions that would allow an evaluation of the additional
Fig. 3 The predicted number of IPD cases averted by PCV10 vaccination in Kilifi with respect to the number of doses administered. In
the dose-efficacy plane (a) the aggregated dose efficiency of the alternative introduction strategies within 10 years after the start of
vaccination is shown. Coloured dots and lines represent medians and 95% credible intervals (the number of doses administered is fixed as
taken from the health register). b shows the (incremental) number of doses needed to prevent one (additional) case of IPD. Figures for
cohort vaccination alone and cohort vaccination in year 10 are presented as absolute values; the catch-up scenarios are presented as
incremental values over the next smaller campaign
Table 2 The impact and efficiency of alternative introduction strategies
Introduction of PCV via IPD averted after 10 years Doses administered Incremental NVN NVN
Cohort only 155 (121–193) 204,671 1321 (1058–1698) 1321 (1058–1698)
+ U1 catch-up 173 (134–216) 218,089 757 (618–973) 1263 (1012–1623)
+ U2 catch-up 189 (147–235) 224,952 412 (296–606) 1188 (958–1527)
+ U5 catch-up 220 (172–270) 241,546 543 (403–763) 1098 (894–1405)
The number of vaccine doses needed to prevent a case of IPD (NVN) is used as a measure of efficiency. Incremental NVN refers to the additional number of doses
needed to prevent one additional cases of IPD in respect to cohort introduction with the next smaller catch-up
Flasche et al. BMC Medicine  (2017) 15:113 Page 6 of 10
impact of the catch-up is challenging because of the dis-
similarity of the underlying population and other factors
including vaccine coverage, intensity of pneumococcal
transmission, differences in demographic structure and
population mixing, serotype distribution and prevalence
of epidemiological risk factors such as HIV infection.
As well as extending direct protection to older chil-
dren who are also at high risk of pneumococcal disease,
catch-up campaigns also rapidly increase the proportion
of individuals in the transmitting population who are
protected against VT acquisition and hence onward
transmission. This indirect effect is non-linear, prevent-
ing a high number of infections for each increment in
vaccine coverage when that coverage is low but suffering
from a saturation effect for higher coverage levels. As a
result, predictions of the optimal extent of catch-up
campaigns need to account for these non-linear effects;
i.e. they need to incorporate transmission dynamics.
Most of our posterior estimates that had an inform-
ative prior were similar to that prior, showing that in
most instances the model is able to match the data well
using the pre-specified parameter space. The notable ex-
ception was the vaccine efficacy against carriage in tod-
dlers. While the model was unable to replicate the
observed steep decrease in VT prevalence following vac-
cination using the mean prior estimate of 36% efficacy,
the posterior suggests a mean efficacy of 55% which has
been observed in other sites [23] and falls well into the
range of the prior estimate.
We have restricted our analyses to catch-up campaigns
that targeted age groups under 5 years of age, as those
were deemed feasible both from a programmatic and a
supply point of view. However, including older children
may well be efficient, in particular in settings where
older children contribute substantially to the transmis-
sion of pneumococci. Also, we have not considered pro-
grammatic issues associated with implementation of
catch-up campaigns. Due to the immense additional
burden on available staff, catch-up campaigns can dis-
rupt routine immunisation services. Furthermore, we
have studied the most efficient use of PCV10 supply but
not the cost-effectiveness or affordability of catch-up
campaigns for PCV10 introduction. One of the major
differences in a cost-effectiveness analysis is that it takes
into account the higher delivery costs of vaccine through
a supplementary immunisation activity. Assuming that
doses delivered as part of a PCV10 catch-up campaign
were up to 75% more expensive than doses delivered
through the routine EPI schedule, however, did not
qualitatively change our findings on the superior effi-
ciency of catch-up programmes.
We did not account for population growth in our
model, which may impact the transmission dynamics in
the post-vaccination era and hence on our findings.
However, modelling work predicting the impact of
PCV10 in Kilifi from pre-vaccination data has shown
that accounting for population growth in Kilifi is un-
likely to qualitatively change the prediction but only
slightly reduces the long-term impact of vaccination on
IPD [34]. As the impact of a catch-up campaign is
mostly visible within a few years after vaccination, it is
likely largely unaffected by long-term changes in demo-
graphics. Hence, accounting for population growth is
likely to further favour the use of catch-up campaigns
for introduction of PCV. Other models have taken into
account more of the diversity of pneumococcal serotypes
by either modelling them individually or by using finer
groupings [19, 34–36]. Despite the considerable hetero-
geneity of serotypes in regard to their ecology within
both our VT and NVT group, our model captures the
post-vaccination dynamics well. The impact of catch-up
campaigns largely concerns the acceleration of long-
term impact of the programme, and hence nuances in
the dynamics of specific serotypes are unlikely to quali-
tatively change our findings. We have not taken into
account potential underreporting of IPD episodes. How-
ever, extra attention has been paid to that during the
study period; the same procedures were followed at Kilifi
hospital so that ascertainment has not changed, and
hence any such bias in our estimates for relative impact
of PCV introduction strategies should be minimal. Fur-
ther, our primary objective was to estimate the relative
impact of PCV10 introduction with and without catch-
up campaigns. Hence, we chose not to incorporate
factors that influence the absolute impact of pneumo-
coccal vaccination but that should make little difference
to the impact of catch-up campaigns relative to cohort
introduction, such as impact on otitis media, pneumonia
or mortality, secular trends, antibiotic consumption, co-
morbidities or cost. We fit age-group- and serotype-
group-specific pathogenicity and assumed that those
would stay unchanged during the study period. While vac-
cination may have led to a disproportionate emergence of
some serotypes and hence changes in serotype-group
pathogenicity, Nurhonen and Auranen have shown that
the assumption of proportional expansion and hence
unchanged pathogenicity generally holds [37], and our
model fits well to both pre- and post-vaccination IPD
and carriage without the need for allowing a change in
pathogenicity.
The generalisability of our results beyond KHDSS is
dependent on a number of factors. We show in a sensitiv-
ity analysis the robustness of our findings to vaccine
coverage, vaccine efficacy against the carriage and IPD,
the ratio of toddler to infant protection, the duration of
vaccine-induced protection and the between-serotype
group competition (see Additional file 1: Figure S3 and
Figure S4). However, other factors that could not be
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systematically assessed in this analysis include transmis-
sion intensity and serotype distribution. In settings with
higher transmission intensity, birth cohort PCV introduc-
tion likely takes longer to establish full herd effects. As a
result, catch-up campaigns that accelerate the build-up of
herd protection have the potential to prevent more IPD
cases and hence be an even more efficient strategy for
PCV use. Furthermore, we did not account for potential
cross-reactivity of PCV10 against serotypes 6A and 19A,
which has been reported previously [38, 39]. However,
both 6A and 19A carriage prevalence increased in the
post-vaccination era in Kilifi [11].
We assumed that two PCV10 doses in infancy, given
as part of the routine EPI schedule, are similarly effica-
cious at preventing VT carriage and disease as a single
catch-up dose in toddlers and young children. Fitting to
the data from Kilifi, our model did not reject this
hypothesis. While our results are robust to factors in-
cluding these differences in relative protection in infants
and toddlers and variable vaccine coverage (proportion
of protected infants and toddlers), the number of doses
that are administered to establish protection could have
a larger impact. Twelve months after the introduction of
PCV10 in Kilifi, 76% of infants eligible for three doses of
PCV10 aged less than 1 year had received at least two
doses of PCV10, and 62% of children 1–4 years old had
received at least one dose. We have chosen the dosing of
catch-up campaigns to align with what was rolled out in
Kilifi; however, other dosing regimens have been used
[40], notably in south Africa with two doses in infancy
followed by a booster dose at 9 months of age [41]. In
our analysis we assume for simplicity that all children
receive the exact number of doses that in this analysis
was deemed sufficient to induce protection. Drop-out
rates in Kilifi are relatively low; e.g. more than 97% of in-
fants who received one dose go on to receive a second
dose before 1 year of age, but including drop-outs in the
analysis would further decrease the efficiency of the
cohort introduction in comparison to the catch-up
campaigns. To define protection in our model, we used
two doses in infancy and one dose for catch-up cam-
paigns as a protective schedule but assumed that vacci-
nated children would eventually receive three doses as
part of the routine schedule or alternatively two doses
or one dose if part of the catch-up campaign in <1 year
old or older children, respectively. Assuming instead
that the children protected through routine immunisa-
tion and catch-up campaigns had received two doses
and one dose, respectively, did not qualitatively change
the results.
Conclusions
Pneumococcal conjugate vaccines (PCVs) are among the
most expensive vaccines currently available and make up
more than 30% of the annual budget of Gavi. Proposed
ways to use PCVs more efficiently include a potential
reduction in the number of infant doses if herd effects
have been established [42] or a dilution of the current for-
mulation. We show here that catch-up campaigns present
an important, readily available tool which can increase the
efficiency of the PCV’s impact on disease at introduction.
For countries yet to introduce, or potentially also for
countries with lagging coverage, strategies that include
catch-up campaigns warrant serious consideration.
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